Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Chimeric Therapeutics Ltd. ( (AU:CHM) ) has provided an update.
Chimeric Therapeutics Limited has applied for quotation on the ASX of 6,900,993 new ordinary fully paid shares, with an issue date of 4 May 2026. The newly issued securities form part of a previously announced transaction, signaling an expansion of the company’s listed share capital and potential additional funding or consideration that may influence its capital structure and market liquidity.
More about Chimeric Therapeutics Ltd.
Chimeric Therapeutics Limited is an Australian biotechnology company listed on the ASX under the code CHM. The company operates in the life sciences sector, focusing on developing therapeutic products, with its ordinary fully paid shares traded on the Australian securities market.
Average Trading Volume: 220,497
Technical Sentiment Signal: Sell
Current Market Cap: A$7.29M
See more data about CHM stock on TipRanks’ Stock Analysis page.